Attovia Therapeutics (ATTO) investor relations material

Company formation and platform overview

• Founded in June 2023 with a focus on immune-mediated disease using the ATTOBODY platform.

• Built a sustainable pipeline of near development-stage multi-specifics and completed an upsized IPO.

• ATTOBODYs are biparatopic, modular nanobody-based biologics with high affinity and potency.

• Platform enables multi-specific formats, tunable affinity, and conditional bispecifics, with a 100% success rate in over 15 campaigns.

• Nanobodies offer low immunogenicity and flexibility, validated by commercial and late-stage clinical products.

Lead program ATTO-1310: Clinical progress and differentiation

• ATTO-1310 targets IL-31 ligand for chronic itch, moving into phase II for CPUO and high itch AD.

• Targeting the ligand avoids reverse dose efficacy issues seen with receptor-targeting drugs and may offer faster itch relief.

• Biparatopic binding provides high potency, near-zero off rate, and supports quarterly dosing.

• Phase I data show excellent safety, full IL-31 suppression for at least 12 weeks, and rapid, deep itch relief.

• Responder rates at week four: 65% for CPUO (vs. 18% for dupilumab) and 44% for high AD (vs. 28% for nemolizumab).

Upcoming clinical milestones and study design

• Full phase Ib results for ATTO-1310 expected in Q4, including safety, target engagement, and durability of response.

• Phase II studies in CPUO and high itch AD to start in H1 next year, with large, global, placebo-controlled designs.

• CPUO phase II will enroll 300 patients, using two active doses and a large placebo group, with FDA feedback incorporated.

• AD phase II focuses on mild to moderate patients with high itch, targeting an underserved segment.

• IND clearance received for cholestatic pruritus study in China, expanding into systemic itch indications.